Oppenheimer cuts Axsome Therapeutics target to $183

Oppenheimer lowered its price target on Axsome Therapeutics (AXSM) to $183 from $185, maintaining an Outperform rating, after the FDA issued a Refusal to File letter for AXS-14 due to incomplete NDA data. Axsome plans to initiate another trial mirroring the first trial's design in Q4 2025, targeting potential approval around 2028. Despite this setback, Oppenheimer remains optimistic, believing the market had not significantly valued AXS-14, and anticipates focus shifting to Auvelity and Symbravo.

Analysis

Oppenheimer has modestly adjusted its price target for Axsome Therapeutics (NASDAQ:AXSM) to $183 from $185, while importantly maintaining an Outperform rating on the stock, which traded at $111.12 post-announcement. This revision directly follows the U.S. Food and Drug Administration's (FDA) issuance of a Refusal to File (RTF) letter concerning the New Drug Application (NDA) for AXS-14, a candidate for fibromyalgia treatment. The FDA's refusal stemmed from perceived incompleteness in the NDA, specifically related to the design of the second pivotal trial. Axsome Therapeutics plans to address this by initiating a new trial in the fourth quarter of 2025, designed to mirror the successful first trial, which consequently postpones potential AXS-14 approval to approximately 2028. Oppenheimer’s commentary suggests that the market had not previously assigned substantial value to AXS-14, implying the RTF letter's impact on Axsome’s valuation may be contained. The firm anticipates investor focus will now intensify on Axsome's existing revenue-generating product, Auvelity, and the upcoming launch of Symbravo. Despite this regulatory setback for AXS-14, Axsome Therapeutics demonstrates robust financial health, evidenced by impressive gross profit margins of 91.49% and significant year-over-year revenue growth of 72.16% over the last twelve months. Furthermore, Axsome recently settled a patent dispute concerning SUNOSI, permitting a generic version from 2040, indicating a proactive approach to intellectual property management, though the AXS-14 situation highlights the persistent clinical and regulatory risks within the biotech sector.

Key Decisions for Investors

• Re-evaluate the contribution of AXS-14 to Axsome's valuation, considering the substantially delayed timeline to a potential 2028 approval and Oppenheimer's assessment of its limited prior market valuation.
• Increase scrutiny on the commercial performance of Auvelity and the execution of the Symbravo launch, as these assets are now more critical to driving Axsome's near-to-medium-term growth and supporting its current valuation.
• Balance the company's strong underlying financial metrics, such as its 72.16% LTM revenue growth and 91.49% gross profit margins, against the inherent drug development risks underscored by the AXS-14 RTF, and monitor ongoing pipeline progress and regulatory interactions closely.